Persistent biological identity
A person should not be treated as a new biological record every time they enter a new system. EBID is our identity primitive: verify once, reuse safely, audit forever — across studies, institutions, and time.
Why We're Building Ømnimind · Enigma Genetics
That world is over. A person's biology is continuous. Their identity, consent, provenance, and data history should be continuous too.
The questions every system keeps re-asking
That repetition creates friction, cost, risk, and delay. Biological data should not reset every time a person enters a new hospital, joins a new study, or changes providers.
What matters to us
A person should not be treated as a new biological record every time they enter a new system. EBID is our identity primitive: verify once, reuse safely, audit forever — across studies, institutions, and time.
Biological data should not be trapped inside institutions, brokers, or collapsing consumer genomics companies. Their biology. Their consent. Their audit trail. Their economic participation.
Consent today is paperwork — a PDF, a checkbox, a portal click. We're building toward consent that is real-time, revocable, scoped, auditable, tied to proof-of-person, and enforced at the moment of computation.
Biological data without provenance is just an expensive claim. Signachain produces an immutable audit trail using signed records, trusted timestamps, and hash-chained entries — Ømnimind sits on top of that proof layer.
Genomic data can remain sensitive for decades — across a person's life, their children, and lineage. We build with post-quantum cryptography, secure enclaves, encrypted GeneVault storage, and edge-first architecture.
Reuse without governance becomes exploitation. Biological data should only be reusable when the individual has consented, the purpose is clear, the access is logged, and the value exchange is visible.
The thesis
Verify once. Reuse safely. Audit forever.
Ømnimind is the intelligence layer inside Enigma's biological infrastructure. Not a chatbot. Not a generic health assistant. Not a consumer wellness gimmick with a lab report attached.
What we plan to build
Ømnimind works from a person's governed biological record — connected to their Signachain timeline and Health State.
Translate genomic information, lab results, medications, health trends, study opportunities, clinical history, risk signals, and consent requests into useful context.
When new labs, reports, prescriptions, or genomic updates arrive, Ømnimind helps the user understand what changed, what matters, and what should be committed to their record.
Surface who is requesting access, what data they want, why they want it, how long access lasts, whether compensation applies, and what happens if consent is revoked.
Cryptographic proof-of-presence, consent verification, and audit completeness reduce re-screening — keeping individuals engaged across rare disease trials and longitudinal studies.
When biology creates value, the individual should see it. Ømnimind surfaces opportunities, compensation, and dynamic recruitment pricing so the person stays in the value loop.
Computation respects consent at runtime. Vaults are encrypted. Identities are cryptographically bound to the right person. The person is always the center of the system.
What we are not building
What we are building
Infrastructure that helps biological data become persistent, governed, reusable, auditable, and economically aligned. A trusted biological operating layer — one where individuals, researchers, clinicians, and institutions can interact with biological data without rebuilding trust from zero every time.
Enigma is building the rails. Ømnimind is the intelligence that helps people ride them.
Our long-term vision
We Believe...
Biology should not be fragmented.
Identity should not reset.
Consent should not be symbolic.
Data should not be extracted without governance.
Ømnimind exists because the next generation of medicine needs more than storage, more than AI, and more than another app. It needs a trusted biological operating layer.
That is what we are building at Enigma Genetics.